Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC cuts target prices for M&S and Kingfisher

(Sharecast News) - RBC Capital Markets has reviewed its forecasts across the UK retail sector ahead of the upcoming Budget in November, cutting its estimates for Marks & Spencer and Kingfisher. "Our latest relative pricing survey suggests a further polarisation between design and price led offers in homewares, which remains a relatively fragmented market," RBC said in a research note on Monday.

"In the run up to the UK budget on November 26, we expect some consumer uncertainty over tax rises to weigh on sentiment, but lower ticket homewares spend should continue to be resilient."

The broker has cut its target price for M&S (rated 'outperform') from 400p to 375p on the back of weaker clothing margins as the company attempts to win back customers following its recent cyber attack.

"M&S is currently trading at c.11x CY26e P/E which looks fairly undemanding, assuming M&S can execute well post its cyber disruption and is slightly below the middle of its historical range. This is especially so in our view in the context of M&S' loss-making share of Ocado Retail," RBC said.

The target price for Kingfisher ('sector perform' )has been kept at 300p, but earnings estimates have been reduced due to softer performances in France and the UK DIY market in the second quarter.

Kingfisher, RBC said, is trading as 12 times 2025 earnings, falling to 11 times on next year's estimates, which is just below the middle of its historical range.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.